Related Experiment Video
Updated: Mar 25, 2026
06:32
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
8.4K
Prognostic role of Gli1 expression in solid malignancies: a meta-analysis
Ji Cheng1, Jinbo Gao2, Kaixiong Tao2
1Department of General Surgery, Southwest Hospital, Third Military Medical University, Chongqing, 400038 China.
Scientific Reports
|February 23, 2016
Summary
Gli1 overexpression indicates a worse prognosis in most solid tumors. This finding holds true across various cancer types, except for intracranial tumors and cytoplasmic Gli1 expression.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Gli1 is a key downstream target of the Sonic hedgehog pathway in mammals.
- Gli1 is recognized as a proliferative indicator in carcinogenesis.
- The prognostic significance of Gli1 in solid malignancies is not fully understood.
Purpose of the Study:
- To investigate the correlation between Gli1 positivity and clinical prognosis in patients with diverse carcinomas.
- To evaluate Gli1 as a prognostic biomarker in solid tumors.
Main Methods:
- A meta-analysis was conducted, including 39 studies with 4496 cases.
- Data on overall survival and disease-free survival at 3, 5, and 10 years were extracted.
- Odds ratios and the Mantel-Haenszel model were used for quantitative analysis, with subgroup analyses performed.
Main Results:
- Gli1 positivity was significantly associated with worse overall survival and disease-free survival in solid malignancies.
- This negative prognostic effect was consistent across different regions, sample sizes, mean ages, and detection methods.
- However, cytoplasmic Gli1 expression and Gli1 positivity in intracranial tumors did not correlate with poorer 3- and 5-year prognoses.
Conclusions:
- Overexpressed Gli1 is a credible indicator of poorer prognosis in most solid malignancies.
- Gli1's prognostic value may vary depending on cancer type and subcellular localization, with exceptions in intracranial tumors and cytoplasmic expression.
